MedTrace Logo

SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer

NCT04861415 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2023-04-12

No results posted yet for this study

Summary

Random assignment between SBRT and conventionally fractionated boost following HDR brachytherapy for prostate cancer.

Conditions

Interventions

RADIATION

Sterotactic Body Radiotherapy

Hypofractionated stereotactic radiation treatment.

RADIATION

Conventionally Fractionated Radiation

External beam radiation therapy treatment

Sponsors & Collaborators

  • Dr. Gerard Morton

    lead OTHER

Principal Investigators

  • Gerard Morton · Sunnybrook Health Sciences Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-23
Primary Completion
2023-06-23
Completion
2027-12-23

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04861415 on ClinicalTrials.gov